登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301511 证券简称：德福科技 公告编号：2026-004 九江德福科技股份有限公司 第三届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 九江德福科技股份有限公司（以下简称"公司"）第三届董事会第二十次会议于2026年1月15日以现场及 通讯方式召开，经全体董事一致同意，豁免本次会议通知期限。本次会议应出席董事9人，实际出席董 事9人。会议由董事长马科先生主持，相关高级管理人员列席。本次会议的召开符合《公司法》和《公 司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 董事会认为：基于对公司未来发展前景的信心和对公司价值的高度认可，同时为进一步健全公司长效激 励机制、充分调动优秀员工的积极性、提升团队凝聚力、携手共促公司的长远健康发展。公司计划使用 自有资金和自筹资金（含股票回购专项贷款等）以集中竞价交易方式回购公司部分股份，用于实施员工 持股计划或股权激励。本次回购股份价格不超过人民币53.46元 /股（含）；资金总额为不低于人民币 ...

Core Viewpoint - The company announces the conditional redemption terms for its convertible bonds, "Kewo Convertible Bonds," allowing bondholders to sell their bonds back to the company at a specified price during a designated period [2][5]. Group 1: Redemption Terms - Redemption Price: 100.26 RMB per bond (including accrued interest and tax) [1][9]. - Redemption Period: From January 21, 2026, to January 27, 2026 [1][8]. - Payment Date for Redemption Funds: January 30, 2026 [1][10]. - Bondholders have the right to choose whether to redeem their bonds; the redemption is not mandatory [1][5]. Group 2: Conditions for Redemption - The conditional redemption clause is activated if the company's stock price remains below 70% of the bond's conversion price for 30 consecutive trading days during the last two interest years [2]. - If bondholders do not exercise their redemption rights during the specified period, they will lose the right to redeem for the current interest year [1][3]. Group 3: Interest Calculation - The interest rate for the fifth year (November 30, 2025, to November 29, 2026) is set at 1.8%, with the accrued interest calculated to be approximately 0.26 RMB per bond [4]. Group 4: Redemption Process - Bondholders must submit their redemption requests through the Shanghai Stock Exchange trading system during the redemption period [6]. - If a redemption request is not successful on the first day, bondholders can continue to submit requests on subsequent days within the redemption period [7]. Group 5: Trading During Redemption Period - "Kewo Convertible Bonds" will continue to trade during the redemption period but will stop conversion [12]. - If the total face value of the bonds in circulation falls below 30 million RMB due to redemptions, trading will continue until the end of the redemption period, after which an announcement will be made [12].

Group 1 - The company’s controlling shareholder, Fuda Holdings Group Co., Ltd., plans to issue exchangeable bonds to professional investors, backed by a portion of its A-share stock holdings [1] - The exchangeable bonds have been approved by the Shanghai Stock Exchange and the stock has been transferred to a designated trust account to secure the bondholders' rights [1] - The total number of A-shares involved in the collateral is 35,923,567 shares [1] Group 2 - The bond issuance was completed on January 15, 2026, with a total issuance size of 470 million yuan and a maturity of 3 years [2] - The coupon rate for the bonds is set at 0.10%, and the initial conversion price is 17.50 yuan per share [2] - The conversion period for the bonds will start six months after the issuance date and will end the trading day before the bonds are delisted [2]

Summary of Key Points Core Viewpoint - The announcement confirms the completion of a share reduction plan by a major shareholder, Zhang Shihong, who has reduced his holdings in Shanghai Chuangli Group Co., Ltd. Group 1: Shareholding Information - As of the announcement date, Zhang Shihong holds 1,260,000 shares of Shanghai Chuangli Group, representing 0.1949% of the total share capital of the company [1]. Group 2: Share Reduction Plan Implementation - The share reduction plan was disclosed on December 10, 2025, and Zhang Shihong has cumulatively reduced his holdings by 420,000 shares through centralized bidding, completing the reduction plan [1]. - The reduction plan was executed in compliance with relevant laws and regulations, and the actual reduction aligns with the previously disclosed plan [1]. - The reduction plan was not terminated early, and there were no violations of the reduction plan or other commitments [1].

Group 1 - The company, Ganli Pharmaceutical Co., Ltd., has received approval from the Ethiopian Food and Drug Authority for the registration of its insulin glargine injection and pre-filled pen, indicating a significant step in its market expansion in Ethiopia [1][2] - The approved drug, BasalinTM, is indicated for diabetes treatment and is available in two forms: injection and pre-filled pen, both with a concentration of 100 units/ml in a 3ml vial [1] - The insulin glargine is a long-acting insulin that requires daily subcutaneous injection, providing a stable blood glucose level for up to 24 hours [1] Group 2 - Ethiopia has a population of approximately 130 million, with a projected diabetes patient population of around 2.3 million among individuals aged 20-79, representing a prevalence rate of 3.6% [2] - The average annual expenditure on diabetes-related healthcare per patient in Ethiopia is estimated at $96.2 [2] - Sanofi is currently the main supplier of insulin glargine in Ethiopia, with global sales of its insulin products projected to reach €2.855 billion (approximately $2.989 billion) in 2024 [2] Group 3 - As of September 30, 2025, the company has invested a total of 936 million RMB in research and development for the insulin glargine project [3]

Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. has received approval for the supplementary application of Diflunisal tablets, which enhances the company's product line and market competitiveness [1][5]. Group 1: Drug Approval Details - Drug Name: Diflunisal Tablets [2][3] - Dosage Form: Tablet [2][3] - Specifications: 0.25g and 0.5g [2][3] - Registration Category: Chemical Drug [2][3] - License Holder and Manufacturer: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. [2][3] - Approval Conclusion: The drug has passed the consistency evaluation of generic drug quality and efficacy [1][2]. Group 2: R&D Investment - The cumulative R&D investment for the Diflunisal tablet project is approximately 7.1492 million RMB [4]. Group 3: Market Impact - The approval of Diflunisal tablets is expected to enrich the company's product line and enhance the market competitiveness of this product [5].

Meeting Details - The shareholder meeting was held on January 15, 2026, at the company's conference room located at 488 Huixian Road, Jiading District, Shanghai [1] - The meeting was attended by 7 current directors, with 6 present and one independent director, Mr. Huan Anan, absent due to personal reasons [2] Voting and Resolutions - A resolution regarding the completion of certain fundraising investment projects and the permanent allocation of surplus funds to replenish working capital was approved [3] - All resolutions were ordinary voting matters and were passed with more than half of the valid voting rights held by attending shareholders or their representatives [3] Legal Compliance - The meeting was witnessed by Shanghai Guangfa Law Firm, with lawyers Shi Min and Li Lingling present [4] - The legal opinion concluded that the procedures for convening and holding the meeting complied with the Company Law, Shareholders' Meeting Rules, and other relevant regulations, ensuring the legality of the meeting's conveners and attendees [4]

Core Viewpoint - Longyuan Power Group Co., Ltd. has successfully completed the issuance of its second phase of ultra-short-term financing bonds for 2026, aimed at supplementing working capital and repaying interest-bearing debts of the issuer and its subsidiaries [2][5]. Group 1 - The company received authorization from its shareholders on June 17, 2025, to apply for and issue debt financing instruments with a total new scale not exceeding RMB 500 billion (including 500 billion) [1][4]. - The company can register debt financing instruments with the China Interbank Market Dealers Association, with a total new scale not exceeding RMB 800 billion (including 800 billion), and may issue them in installments [1][4]. - The relevant documents for the bond issuance have been published on the China Money website and the Shanghai Clearing House website [2][6]. Group 2 - The first phase of ultra-short-term financing bonds for 2026 was also successfully issued on January 14, 2026, with similar purposes for the raised funds [5][6]. - The company’s board of directors has been authorized to handle related matters within the scope of the authorization granted by the shareholders [1][4].

登录新浪财经APP 搜索【信披】查看更多考评等级 1．重庆长安汽车股份有限公司（以下简称"公司"）本次回购注销原32名激励对象已获授但尚未解除限 售的A股限制性股票共1,161,948股，占回购注销前公司总股本的0.01%。 2．中国证券登记结算有限责任公司深圳分公司确认已于2026年1月15日办理完成公司本次部分限制性股 票回购注销事宜。本次注销符合法律、行政法规、部门规章、规范性文件、公司章程、股权激励计划等 的相关规定。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 3．本次回购注销完成后，公司总股本由9,914,086,060股减少至9,912,924,112股。 公司于2025年9月26日召开第九届董事会第四十五次会议，并于2025年10月24日召开2025年第一次临时 股东大会，审议通过了《关于调整A股限制性股票激励计划回购价格及回购注销部分限制性股票的议 案》。详细内容见2025年9月27日披露在巨潮资讯网（www.cninfo.com.cn）及《中国证券报》《证券时 报》《证券日报》《上海证券报》的《关于调整A股限制性股票激励计划 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司高级管理人员王文旭先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山东三维化学集团股份有限公司（以下简称"公司"）于2025年9月16日在《中国证券报》、《证券时 报》及巨潮资讯网（http://www.cninfo.com.cn）披露了《关于高级管理人员减持股份的预披露公告》 （公告编号：2025-031），公司高级管理人员王文旭先生计划自上述公告披露之日起15个交易日后的3 个月内（2025年10月16日至2026年1月15日，窗口期内不得减持）以集中竞价交易方式减持其持有的本 公司股份不超过120,656股（占本公司总股本的比例不超过0.0186%）。 近日，公司收到王文旭先生发来的《股份减持计划实施结果的告知函》，截至本公告披露日，王文旭先 生本次股份减持计划期限已届满，现将具体实施结果公告如下： 一、股东减持情况 1、股东减持股份情况 ■ 注：本表中的"比例"系四舍五入后保留四位小数的结果。 王文旭先生本次减持的股份来源于公司股权激励计划 ...